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Stroke is one of the leading causes of death worldwide and its effective protective 
treatment is still missing.  
Nicotinic acid has been a widely used substance to modify lipid profiles for many years 
and it successfully prevents clinical cardiovascular diseases. Recently explored 
receptor, GPR109A, causes its effect and it was found to be expressed in spleen, 
adipose, and immune cells including macrophages. The aim of this work is 
to investigate the effect of nicotinic acid on the infarct size during cerebral ischemia 
and to determine the role of macrophages in its effect. 
We compared two groups in our experiments, transgenic CD11bDTR mice and control 
wild type (WT) mice. Both groups were treated with diphtheria toxin (DT), then 
a middle cerebral artery occlusion was performed and afterwards mice were treated 
with either nicotinic acid or vehicle.  
We have found depletion of macrophages in CD11bDTR group induced by DT 
treatment and depletion of macrophages in WT group treated with nicotinic acid. We 
also found significant difference in infarct volume in the wild type mice that are treated 
with nicotinic acid than their corresponding control. 






Univezita Karlova v Praze 
Farmaceutická fakulta v Hradci Králové 
Katedra farmakologie a toxikologie 
 
Kandidát: Barbora Pokorná 
Školitel: Doc. PharmDr. Petr Pávek Ph.D. 
Školitel specialista: Prof. Dr. med. Markus Schwaninger 
Název práce: Účinek kyseliny nikotinové na aktivaci makrofágů při iktu 
 
 
Iktus se řadí k jedné z nejčastějších příčin úmrtí na světě a jeho efektivní terapie s 
protektivním účinkem stále chybí. 
Nikotinová kyselina se široce terapeuticky používá pro ovlivnění lipidového spektra 
a jsou také známy její kardiovaskulárně preventivní účinky. Nedávno objevený 
receptor, GPR109A, pravděpodobně zprostředkuje její účinek a nachází se ve slezině, 
tukové tkáni a imunitních buňkách včetně makrofágů.  
Cílem této práce je zjistit, jaký efekt má nikotinová kyselina na rozsah iktu a jakou roli 
hrají makrofágy v jejím účinku. 
Při experimentech jsme srovnávali dvě skupiny myší, geneticky upravené myši 
CD11bDTR a kontrolní wildtype skupinu. Obě skupiny byly léčeny difterotoxinem, 
následně byl operativně vyvolán iktus a polovina myší byla posléze léčena kyselinou 
nikotinovou  a polovina pouze vehikulem. 
Zjištěným výsledkem byla deplece makrofágů ve skupině geneticky modifikovaných 
CD11bDTR myší vyvolaná podáním difterotoxinu. V kontrolní skupině wildtype myší 
vyvolalo podání kyseliny nikotinové rovněž depleci makrofágů. Zároveň byl v této 
skupině prokázán nižší rozsah iktu oproti ostatním skupinám. Dle našich výsledků se 




AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
APC  antigen presenting cell 
ATP  adenosine triphosphate 
BBB  blood brain barrier 
BSA  bovine serum albumine 
CAD  caspase-activated deoxyribonuclease 
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FST  Fine Science Tools 
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1.1.1. Definition and epidemiology of stroke 
 
The term stroke, also referred to as cerebrovascular accident (CVA), broadly refers 
to neurologic symptoms and indicates interrupted blood flow to brain tissue (Nestler 
Eric 2009). Stroke is one of the leading causes of morbidity and mortality worldwide. It 
is the third leading cause of death after cardiovascular diseases and cancer 
in industrialized countries (Thorvaldsen et al. 1995). According to WHO estimates, 
15 million people each year suffer strokes and 5 million are left permanently disabled. 
Stroke accounts for a higher proportion of deaths among women than men 
(11% vs. 8.4%). Among women, 3 million deaths from stroke occur annually (WHO, 
2004).  
Consequences of stroke are in enormous medical, economic, and personal costs. 
Survivors of stroke are often affected by serious long-term disabilities such as paralysis 
and disruption of higher cognitive functions such as speech. These patients are unable 
to resume work and other activities, and often need extensive long-term care 




Stroke occurs upon disruption of blood flow to brain tissue caused by obstruction 
or hemorrhage and that separates the two primary types of stroke- hemorrhagic 
and occlusive.  
A hemorrhagic stroke is caused by bleeding from a vessel and it usually occurs 
in selected parts of the brain, including the basal ganglia, cerebellum, brainstem, 
or cortex. Intracerebral hemorrhage is divided in the intraparenchymal, epidural, 
subdural, or subarachnoid type (Nestler Eric 2009). 
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An occlusive stroke, also called cerebral ischemia, occurs when the blood vessel 
becomes blocked. Blockage can be caused by embolic, atherosclerotic, or thrombotic 
occlusion of cerebral vessels. Vascular occlusion results in neurologic deficits 
and in a loss of functions controlled by the affected region (Nestler Eric 2009). 
Cerebral ischemia can be differentiated into focal and global cerebral ischemia. Focal 
cerebral ischemia results in a damage of the same region where a blockage in an artery 
occurs. However, damage can be reduced by forming collateral blood supply in contrast 
to global cerebral ischemia. Focal cerebral ischemia is differentiated into transient 
and permanent cerebral ischemia. In our study a mouse model of permanent cerebral 
ischemia is used to investigate ischemic stroke (Hossmann 1998). 
 
1.1.3. Aetiology and risk factors 
 
Risk factors for stroke can be classified as modifiable, potentially modifiable and 
non-modifiable (Sacco 1997). 
The risk factors for stroke that can not be changed include age, gender, family history 
and ethnicity (Sacco 1997). 
Modifiable factors that are associated with an increased risk of stroke involve 
the history of hypertension, current smoking, waist-to-hip ratio, diet risk score 
(increased risk associated with increased consumption of red meat, organ meats 
or eggs, fried foods and cooking with lard), lack of physical activity, diabetes mellitus, 
more than 30 alcoholic drinks per month or binge drinking, psychological stress, other 
heart problems, and cholesterol (O'Donnell et al.). According to the INTERSTROKE 
study (O'Donnell et al.), all of these factors are linked with ischaemic stroke. Only 





Successful treatment can be achieved only with appropriate therapy.  
Therapy depends on the type of stroke and also on the time after onset of stroke and it 
always aims to reduce or prevent brain infarction and minimize the long term disability 
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and stroke-related mortality. Stroke therapy always includes medical treatment 
and sometimes also surgical treatment. Initial treatment for ischemic stroke involves 
removing of the blockage and restoring of blood flow, which can be achieved 
with trombolysis. Recombinant tissue plasminogen activator (rt-PA) is the only 
licensed drug for intravenous use in highly selected patients within three hours of the 
event (Grotta and Marler 2007). One of the possible side effects of rt-PA and other 
thrombolytic drugs used in intra-arterial therapy include serious bleeding in the brain, 
which can be fatal. Anyhow, thrombolysis is the only instrument of reversing vessel 
obstruction and inducing reperfusion. Other treatment is widely used as secondary 
prevention such as antiplatelet medication and anticoagulants to help prevent 
the formation of blood clots and to reduce the risk for recurrent stroke. The choice 
of this medical treatment is very individual, long term and does not affect the lysis 
of the clot. However, therapy that is effective after several hours after onset of cerebral 
ischemia is still missing. 
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1.2. PATHOPHYSIOLOGY OF CEREBRAL ISCHEMIA 
 
The brain represents only 2% of the body’s total mass but it uses approximately 
20% of the body’s oxygen supply, and blood flow to the brain uses about 15% of total 
cardiac output (Nestler Eric 2009). In the acute phase of focal cerebral ischemia, brain 
vessel becomes occluded. It results in insufficient oxygen and glucose delivery and 
serious neuronal damage can occur within minutes of an ischemic event (Nestler Eric 
2009).   
Complex series of cellular and molecular events is rapidly set in cascade that leads 
to cell death: excitotoxicity and ionic imbalance, periinfarct depolarization, 
inflammation and programmed cell death (apoptosis) (Dirnagl et al. 1999). These 
processes are overlapping and each of these events occurs in a distinct time frame from 
the cerebral ischemia onset (Fig.1). The relative contributions of each process are 
believed to vary significantly in relation to the level of cerebral blood flow.  
In the core of an infarct where blood flow is most severely restricted, the main process 
is energy failure and rapid necrotic cell death. This core is surrounded by reversibly 
injured area called ischemic penumbra, where collateral blood flow can evade the full 
effects of the stroke (Liu et al.). 
 
Fig. 1. Cascade of damaging events in focal cerebral ischaemia (Dirnagl et al. 1999). 
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1.2.1. Phase of excitotoxicity, ionic imbalance and periinfact depolarization 
 
Oxygen and glucose deficit caused by ischemia incident leads to deficiency 
of adenosine triphosphate (ATP) produced by oxidative phosphorylation 
in mitochondria. ATP is necessary to maintain and restore ionic gradients, 
e.g. by Na+/K+ ATPase nessesary for the action potential (Doyle et al. 2008).  
Energy failure leads to ionic disbalance and membrane depolarization. It allows 
the excitatory neurotransmitter glutamate is released and causes increased intracellular 
Ca2+, Na+, Cl- levels while K+ is released into the extracellular space. Release 
of glutamate and K+ can cause further peri-infarct depolarizations (Doyle et al. 2008). 
Due to ionic disbalance, water shifts to the intracellular space via osmotic gradients 
which may result in oedema affecting the perfusion of surrounding tissue and resulting 
in increased intracranial pressure, vascular compression and herniation (Dirnagl et al. 
1999). Glutamate also activates N-methyl-D-aspartate (NMDA) 
and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.  
Opening of NMDA channels and changing in a subunit of AMPA channels, leads 
to further membrane depolarization and greater calcium influx, exacerbating  
intracellular calcium overload (excitotoxicity) (Doyle et al. 2008). 
Calcium, the universal intracellular messenger, overactivates many catabolic enzymes 
such as calcium dependent proteases, lipases and DNAses and it leads to death of many 
cells in the ischemic core. Among other enzymes, calcium triggers neuronal 
nitric-oxide synthese (NOS) that synthesize nitric oxide (NO). It reacts with 
a superoxide anion and form highly reactive peroxynitrite, a potent oxidant (Dirnagl et 
al. 1999). This production of free radicals and oxidative stress leads to over-activation 
of poly(ADP-ribose)polymerase-1 (PARP-1), a DNA repair enzyme, which catalyzes 
the transformation of β-nicotinamide adenine dinucleotide (NAD+) into nicotinamide 
and long polymers of poly(ADP-ribose). When PARP-1 is over-activated it depletes 
cells of NAD+, impairing NAD+ dependent processes such as anaerobic glycolysis 
and mitochondrial respiration, which leads to ATP starvation, energy failure 
and neuronal death. Oxygen free-radicals also serve as important signaling molecules 




1.2.2. Phase of inflammation 
 
The inflammatory response is a composite process that involves many different cell 
types, inflammatory mediators and extracellular receptors 
 
The Cellular Inflammatory Response 
 
Stroke causes neutrophilia, lymphocytopenia and an increase in the number 
of circulating monocytes (Ross et al. 2007) which contributes to ischemic damage.  
First cells that accumulate in the brain as early as 30 minutes after permanent middle 
cerebral artery occlusion (MCAO) are neutrophils. Its recruitment to ischemic brain 
begins with neutrophil rolling on activated endothelial blood vessel walls, mediated 
by selectins (e.g. P-selectin, E-selectin) followed by neutrophil activation 
and adherence, mediated by integrins and immunoglobins. Adhesion to vessel 
is enabled through a contact between integrins and endothelial intercellular adhesion 
molecule–1 (ICAM-1). Subsequently, neutrophils transmigrate into the cerebral 
parenchyma, a process facilitated by blood brain barrier (BBB) disruption (McEver 
2001). The recruitment of neutrophils can obstruct the microcirculation which can be 
followed by the increased severity of ischaemia (Dirnagl et al. 1999). Moreover, 
neutrophils cause release oxygenfree radicals and proteolytic enzymes causing 
the tissue damage. 
The bone marrow derived cells accumulate in the ischemic brain and become 
the predominant cell in the late stages of infarct. They bind to vascular cell adhesion 
molecule (VCAM), transmigrate in the cerebral parenchyma and persist in the ischemic 
brain for weeks following stroke (Danton and Dietrich 2003). 
Microglia/blood derived macrophages play a key role in the development of ischaemic 
lesions. Althought the initial infiltration leads to worsening of tissue damage 
and exacerbation of neurological deficits, in the later phases, microglia can phagocytose 
debris, attack microorganisms that may infect the damaged area and release cytokines 
that promote glial scar formation (Danton and Dietrich 2003). 
Microglia and perivascular cells mediate the intrinsic neuroinflammatory response. 
Microglia are generally considered to be derived from the monocytic lineage. They 
reside in a ‘‘resting’’ but vigilant state throughout the parenchyma and express few 
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surface molecules identifying them as potential phagocytes. Four to six hour after 
ischemia, microglia/macrophages become activated and migrate to site of injury 
and asume an ameboid morphology, differentiate, phagocytose and secrete a wide 
variety of molecules icluding the same markers as peripheral macrophages (Eglitis and 
Mezey 1997). In this state they are virtually indistinguishable from peripheral 
macrophages (Danton and Dietrich 2003). 
Lymphocytes, ordinarily excluded from the central nervous system (CNS), appear 
within 24 hours in post ischemic brain (Schroeter et al. 1994). Although the exact 
mechanism producing their infiltration into the brain remains unclear, BBB disruption 
plays a major role in the influx, either by directly allowing free lymphocyte movement, 
or by leakage of brain antigens resulting in the transmigration of activated lymphocytes 
(Danton and Dietrich 2003). Lymphocytes appear to contribute to development 
of the lesion in the cortex (Hurn et al. 2007) 
 
The cytokine inflammatory response 
 
Injured brain produces cytokines and chemokines which initiate a localized 
inflammatory response and contribute to stroke related brain injury. 
During ischemia, cytokines, such as interleukin-1 (IL-1), IL-6, tumor necrosis factor-α 
(TNFα), transforming growth factor (TGF-β) produced by a variety of activated cell 
types. 
Production of IL-1 is increased in microglia, astrocytes, and neurons. Among other 
possible deleterious effects of IL-1 (fever, arachidonic acid release, enhancement 
of NMDA mediated excitotoxicity, and stimulation of nitric oxide synthesis) 
is the additional role of IL-1 recruitment and adhesion of neutrophils through 
up-regulation of E-selectin, ICAM-1, ICAM-2, and VCAM-1 on cerebral endothelial 
cells (Huang et al. 2006). 
Expression of IL-6 appears 3hours after occlusion, and it is unclear whether its effect is 
beneficial or detrimental in the context of stroke. On the one hand, it has 
proinflammatory role and its biological activity overlaps with those of IL1, however, 
IL-6 also has antiinflammatory properties due to its ability to induce IL-1 receptor 
antagonist synthesis (Danton and Dietrich 2003). 
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Up-regulation of TNF-α has shown to aggravate the ischemic injury and like IL-1, 
TNF-α promotes neutrophil accumulation and transmigration (Huang et al. 2006). 
In addition, TNF-α disrupts the blood-brain barrier and stimulates the induction of other 
inflammatory mediators. 
Another cytokine, TGF-β was found to be neuroprotective in the pathogenesis of stroke 
(Huang et al. 2006). 
Besides cytokines, endothelial cells, microglia, neurons, platelets, leukocytes, 
and fibroblasts injured brain produces chemokines such as cytokine-induced neutrophil 
chemoattractant (CINC) and monocyte chemoattractant protein (MCP) which attracts 
neutrophils and monocyte towards their target in ischemic tissue (Huang et al. 2006). 
1.2.3. 	euronal apoptosis 
 
Apoptosis or programmed cell death is an active process of self-destruction eliminating 
the damaged or unnecessary cells. In the ischemic brain it occurs in the area 
surrounding the core, called penumbra, sustaining milder injury and where ATP is still 
preserved (Doyle et al. 2008). Apoptosis is preferred in this area because cells 
undergoing apoptosis minimize damage and disruption to neighboring cells. It is 
triggered by a wide array of stimuli including oxygen free radicals, death receptor 
ligation, DNA damage, protease activation and ionic imbalance (Doyle et al. 2008). 
Cerebral ischemia triggers two pathways of apoptosis- the intrinsic and extrinsic 
pathway. 
The intrinsic pathway is originated from release of cytochrom c from the outer 
mitochondrial membrane caused by ionic disbalance and mitochondrial swelling 
(Broughton et al. 2009). A lot of facilitating factors are included in this pathway- 
proteins from Bcl-2 family either promote (Bax, Bak Bad, Bim, Bid) or prevent (Bcl-2, 
Bcl-XL, Bcl-w) pore formation in the outer membrane which promotes the cytochrome 
c release (Doyle et al. 2008). Release of cytochom c leads to the downstream activation 
of caspases through activation of an apoptosome complex[apoptosis- activating factor 
(APAF1) plus pro-caspase 9] in the presence of dATP (Dirnagl et al. 1999). It promotes 
activation of caspase 3 (Dirnagl et al. 1999), a key mediator in the intrinsic pathway 
(Broughton et al. 2009) and it initiates the irreversible phases of apoptosis by cleaving 
homeostatic, cytoskeletal, repair, metabolic, and cell signaling proteins (Doyle et al. 
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2008). Also further DNA fragmentation is caused by cleaving DNA repair enzymes, 
such as poly (ADP-ribose) polymerase (PARP) (Broughton et al. 2009) 
and by activating capase-activated deoxyribonuclease (CAD). Caspase activation can 
be modulated by protein inhibitors of apoptosis (IAP) and indirectly by secondary 
mitochondria-derived activator of caspase (Smac/Diablo) (Doyle et al. 2008). 
Extrinsic mechanism, also referred to as the death receptor pathway, originates from 
the activation of cell surface death receptors which belong to the necrosis factor 
receptor (TNFR) superfamily. This includes many receptors, among other Fas receptor. 
When a ligand of this receptor (FasL) is bound, an adaptor molecule Fas-associated 
death domain (FADD) protein is bound to procaspase-8 by interacting with its death 
effector domain. This complex (FasL–Fas–FADD–procaspase-8) is referred 
to as death-inducing signaling complex (DISC) and releases caspase-8 
by the proteolytic cleavage. Subsequently caspase 8 in turn activates caspase-3 and this 
effector caspase cleaves PARP and activates CAD, leading to DNA damage and cell 
death as in intrinsic pathway. Caspase-8 can also activate one of the Bcl-2 family 




1.3. ICOTIIC ACID 
 
Nicotinic acid (niacin; vitamin B3), a member of water soluble vitamins has been used 
to treat a wide range of lipid disorders and to successfully prevent clinical 
cardiovascular disease for nearly 50 years (Meyers et al. 2004). 
It modifies lipid profiles by lowering total plasma cholesterol, triglycerides (TGa), 
very-low-density lipoprotein cholesterol (VLDL-C), and low-density lipoprotein 
cholesterol (LDL-C) and it increases high-density lipoprotein cholesterol (HDL-C) 
(Carlson 2005).  Nicotinic acid (NA) treatment has also been shown to slow 
the progression of atherosclerosis and significantly reduce coronary disease morbidity 
and mortality when taken alone or in combination with statins (Brown and Zhao 2008) 
(Canner et al. 1986). 
Usage of niacin is limited by its side effect- a strong cutaneous vasodilatation called 
flushing- which occurs in 80% by patient first administration (Kamanna et al. 2008). 
It has been reported that niacin flush is mediated by prostaglandin D2 (PGD2) (Morrow 
et al. 1989) and PGE2 produced by Langerhans’ cells in the skin and arachidonic acid 
released by phospholipase A2 (Benyo et al. 2006). Thus, flushing can be reduced 
by alteration the pharmacokinetics of the niacin which has been used in the modified 
release formulation of niacin (McKenney et al. 1994). Also the latest discovered 
inhibitor of the prostaglandin DP1 receptor, laropiprant successfully reduces flushing 
by 80% when combined with niacin in a novel formulation niacin- laropiprant (Cheng 
et al. 2006). However, NA treatment is known to be hepatotoxic (Kamanna et al. 2008) 




Recently, the niacin receptor was discovered and was reported as a G-protein-coupled 
receptor (GPCR) existing in the spleen, adipose, and macrophages (Lorenzen et al. 
2001). This receptor is named as GPR109A, also reffered to as HM74 in humans 
and “protein up-regulated in macrophages by interferon γ (PUMA-G) in mice (Schaub 
et al. 2001). This receptor was shown to couple to members of the Gi family 
of G proteins. 
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In adipocytes, binding of nicotinic acid is reported to inhibit lipolysis by inhibiting 
adenylyl cyclase resulting in decrease in intracellular cyclic adenosine monophosphate 
(cAMP) levels (Aktories et al. 1980). It inactivates protein kinase A, which leads 
to the suppression of hormone-sensitive lipase (Tunaru et al. 2003). 
The beneficial effects of NA are not only mediated through alterations in plasma lipid 
levels but expression of GPR109A was also found in immune cells such as monocytes, 
macrophages and neutrophils which can be regulated by various cyrtokines. Activation 
of Gi in immune cells primarily results in the stimulation of β- isoform 
of phospholipase C or of phosphoinositide-3-kinase γ via G protein βγ-subunits 
released from activated Gi (Gille et al. 2008). Studies describing the novel 
anti-inflammatory role of niacin show that niacin decreases monocyte and macrophage 
adhesion and accumulation in atherogenesis (Gille et al. 2008). 
The most recent finding suggests that NA inhibits the upregulation of MCP-1 
expression in response to interferon γ (IFNγ) in isolated macrophages as well 
as in plaque macrophages. Additionaly, nicotinic acid possibly has effect 





Monocytes originate in the bone marrow from a common haematopoietic stem cell 
(HSC). During their development, myeloid progenitor cells (termed 
granulocyte/macrophage colony-forming units) give rise to monoblasts and then they 
divide and differentiate into pro-monocytes and finally monocytes, which exit the bone 
marrow and enter the bloodstream. They transfer into circulating peripheral blood 
mononuclear cells (PBMcs), which migrate into tissue in the steady state or in response 
to inflammation. They differentiate in macrophages to replenish long-lived 
tissue-specific macrophages of the bone (osteoclasts), alveoli, central nervous system 
(microglial cells), connective tissue (histiocytes), gastrointestinal tract, liver (Kupffer 
cells), spleen and peritoneum (Gordon and Taylor 2005). 
In the blood, monocytes are not a homogeneous population of cells. Two populations 
of-monocytes have been identified in mice. Inflammatory monocytes rapidly exit 
the blood and they are defined as GR1+ (also known as Ly6) CX3CR1low 
(CX3C-chemokine receptor 1). The second group, resident monocytes are defined 
as GR- CX3CR1hi (Geissmann et al. 2003). It is not clear whether these two cells 
represent distinct monocyte populations or if inflammatory monocytes mature into 
resident monocytes (Mosser and Edwards 2008). But human monocytes seem to have 
distinct physiology from that of mouse monocytes. (Passlick et al. 1989). 
Macrophages (MF) differentiate from monocytes and they are phagocytic cells that 
recyclate iron and hemoglobin from erytrocytes. They are also involved in the removal 
of cellular debris that is generated during tissue remodelling, and rapidly and efficiently 
clear cells that have undergone apoptosis. MF are essential for host defense- they are 
one of the primary sensors of danger in the host. The endogenous danger is detected 
through Toll-like receptors (TLRs), intracellular pattern- recognition receptors, 
the IL-1R. Majority of them transfers signal through the adaptor molecule myeloid 
differentiation primary-response gene 88 (MyD88) (Mosser and Edwards 2008).  
MF have remarkable plasticity that allows them to efficiently change their phenotype, 
and their physiology can be markedly altered by both innate and adaptive immune 
responses. MF have been classified according to T- cell literature, where M1 MF 
represent one extreme and M2 MF represent another depending on the cytokine 
 
 23 
response that they induce.  M1 MF represent classically activated MF and M2 
alternative activated MF (Gratchev et al. 2001; Mosser and Edwards 2008). 
The response of M1/M2 MF can influence whether Th1/Th2 types of inflammatory 
responses occur (Mills et al. 2000). 
Althought monocyte and MF heterogenity and nomenclature are subject of discussion 
(Geissmann et al.; Gabrilovich and Nagaraj 2009), M2 designation encompasses cells 
with dramatic differences in their biochemistry and physiology. Hence, new grouping 
of MF populations was described based on three different homeostatic activities — host 
defence, wound healing and immune regulation (Mosser and Edwards 2008). 
1.4.1. Classically activated macrophages 
 
Classically activated MF represent products of a cell- mediated immune response 
with microbicidal or tumoricidal activity. 
They arise in response to adaptive or innate immune signal. During innate immune 
response natural killer (NK) cells produce interferon-γ that is also a product of TH cells 
or CD8+ cells during adaptive immune response. Additionally, classically activated MF 
can be activated by tumor necrosis factor, a product of antigen-presenting cells (APC), 
which is induced by a TLR ligand action in a MyD88- dependent manner (Mosser and 
Edwards 2008). 
Ligation of TLR or TNF receptor may activate nuclear factor-κB and mitogen-activated 
protein kinases, IFNγ receptor ligation activates signal transducer and activator 
of transcription molecules. Combination of all these transcription factors triggers all 
genes involved in the activation of classically activated MF (O'Shea and Murray 2008). 
In answer to IFNγ and TNF signal, classically activated MF can secrete 
pro-inflammatory cytokines, produce increased amounts of superoxide anions 
and oxygen and nitrogen radicals to increase their killing ability (Dale et al. 2008). 
The pro-inflammatory cytokines produced by classically activated macrophages are 
for example, IL-1, IL-6 and IL-23. They have been associated with the development 
and expansion of Th17 cells, which can contribute to autoimmune responses (Bettelli et 
al. 2006). Classically activated MF can also produce IL-12 to promote 
the differentiation of Th1 cells, on the other hand they can also produce IL-27, which 
inhibits various immune responses and negatively regulates Th1 and Th2 cells. 
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Cytokines and mediators produced by classically activated MF can also lead 
to host-tissue damage, therefore their activation must be tightly controlled (Mosser and 
Edwards 2008). 
 
1.4.2. Wound-healing macrophages 
 
Wound healing MF can develop also in response to innate or adaptive signals. They are 
generated in presence of IL-4 which can be produced by Th2 cells or by granulocytes 
(Brandt et al. 2000). These macrophages are poor APC and may inhibit T-cell 
proliferation and they produce minimal amount of pro-inflammatory cytokines. 
Their primary function seems to be related to wound healing due to their ability secrete 
components of the extracellular matrix (Mosser and Edwards 2008). 
 
1.4.3. Regulatory macrophages 
 
Regulatory MF are generated in response to various stimuli, including immune 
complexes, prostaglandins, GPCR ligands, glucocorticoids, apoptotic cells or IL-10, 
produced by regulatory T cells (Mosser and Edwards 2008). 
The most important and reliable characteristic of regulatory MF is their 
anti-inflammatory activity. To induce this activity, two stimuli are needed, while 
the first signal has little or no stimulatory function on its own. However, when a second 
stimulus is added, such as a TLR ligand, macrophages start to produce IL-10 (Edwards 
et al. 2006), which suppress immune response by inhibition of production and activity 
of various pro-inflammatory cytokines and it can induce the expansion of Th2 cells. 
In addition to IL-10 production, these regulatory MF also downregulate IL-12 
production; Due to IL-10 production, regulatory MF are inhibitors of inflammation, 
while they are able to produce many pro-inflammatory cytokines (Mosser and Edwards 
2008). 
In addition, variety of these regulatory macrophages expresses high levels 




2.1. Equipment and Instrument 
 
Operation microscope SM33   Hund, Wetzlar, GE 
Bipolar tweezers    Erbe, Tübingen, GE 
Centrifuge 5415R    Eppendorf, GE 
Cold light source FLQ 150   Hund and Wetzlar, GE 
Cover glass 24x60 mm   ROTH Karlsruhe, GE 
Cryotome Leica CM3050S   Leica, Mannheim, GE 
Dissection scissor    FST, Heidelberg, GE 
FACSCalibur     Becton Dickinson 
Fat pen     Dako, Dennmark 
Hippocampus spoon    FST, Heidelberg, GE 
Micro liter syringes Hamilton  FST, Heidelberg GE 
Microtome blades S35   Feather, Japan 
Microtube 1,5 ml     Sarstedt, Nümbrecht, GE 
Minimot drill mashine 40/E   Proxxon, Niersbach, GE 
Mini-Vannas iris scissor   FST, Heidelberg, GE 
Needle holder      FST, Heidelberg, GE 
Pasteur pipette     Neolab, Heidelberg, GE 
Pipette      Geiner Bio-One, Frickenhausen, GE 
Pipette tips      Geiner Bio-One, Frickenhausen, GE 
Polysine slides    Thermo Scientific, Braunschweig, GE 
Small scissors     FST, Heidelberg, GE 
Staining dish      Neolab, Heidelberg, GE 
Sterile 15ml Falcons    Sarstedt, Hildesheim, GE 
Tissue freezing medium    Jung,Nussloch, GE 
Tweezers size 6      FST, Heidelberg, GE 
 
 26 
2.2. Chemicals and Comercial Kit 
 
2, 2, 2-Tribromoethanol    Fluka chemicals, Seelze, GE  
2-Methyl-2-butanol     Fluka chemicals, Seelze, GE  
Acetone      Merck, Darmstadt,GE 
Ammonia solution 25%    Merck, Darmstadt, GE 
Bovine serum albumin (BSA)  SIGMA-aldrich Co., USA 
DAB substrate kit for peroxidase  Vector Laboratories, Burlingame, USA 
Diphteria Toxin powder    SIGMA-Aldrich Co., USA 
Distilled water     B Braun, GE 
Formaldehyde 37%     Merck, Darmstadt, GE 
Hydrogen Peroxide    CARL ROTH, Karlsruhe, GE  
Hydroquinone     Fluka chemicals, GE 
Kalium chloride    Applichem, Darmstadt, GE 
Lithium carbonate     Riedel-de Haen, Seelze, GE 
Methanol 100%    J.T.Baker, Deventer, NL 
Mowiol 4-88     Carl Roth, Karlsruhe, GE 
Natrium Chloride    J.T.Baker, Deventer, Holland 
Paraformaldehyde (PFA)   Riedel-de-Haën Seelze, GE 
Silver nitrate      Carlroth, Karlsruhe,GE 
Skin disinfectant (Kodan)    Schülke & Mayer GmbH Nordstedt, GE 
Tri-Sodium citrate     Sigma-Aldrich, Steinheim 
Triton X-100     Merk, Darmstadt, GE 
Tween 20     Carl Roth, Karlsruhe, GE 





CD11b rat anti mouse antigen, Serotec, Cat. No. MCA711G   
Alexa Fluor 488 donkey anti rat IgG (H+L), Invitrogen, USA, Cat. No. 538955 
DAPI (4‘,6‘- diamidino-2-phenylindole), Sigma, Germany 
 
2.4. Computer hardware and software 
 
Scanner Canon 8600F 
Fluorescence Microscope, Leica DM4000B 
Image J 





3.1. METHODS FOR AIMAL EXPERIMET 
3.1.1. Experimental Animals 
 
In our experiments 8-12 weeks old C57BL/6 mice (wild type mice) and transgenic 
CD11bDTR (Duffield et al. 2005) mice were used. 
3.1.2. Anaesthesia and infarct model 
 
Mice were anaesthetised by intraperitoneal injection of 150 µl 2.5% avertin per 10 g 
body weight. To confirm whether mice were sufficiently anesthetized paw-reflex was 
tested. The skin was disinfected at the site of incision. A skin incision was made 
between the ear and the orbit on the left side. The temporal muscle was removed 
by electrical coagulation. The stem of the middle cerebral artery (MCA) was exposed 
through a burr hole and was occluded by micro bipolar coagulation tweezers. 
The wound was continuously washed with isotonic saline during the procedure 
of removing the temporal muscle and temporal bone to avoid the tissue damage 
due to heat produced by coagulation. Surgery was performed under a microscope. Mice 
were kept at a body temperature of 37 °C on a heating pad. The skin was stitched 
with continuous sutures. 
 
Fig. 2. Model of permanent middle cerebral artery occlusion. 
CCA: Common carotid artery; ECA: External carotid artery; ICA: Internal 
carotid artery; MCA: Middle cerebral artery 
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3.1.3. Blood sampling from the mice 
 
Mice were anaesthetised as explained above. The skin was disinfected and abdominal 
cavity was opened. The intestine was gently placed to the left side of the mouse 
in the abdominal cavity to expose the inferior caval vein. Blood probes were taken 
from abdominal caval vein with 1 ml syringe. 
3.1.4. Perfusion of the brain 
 
The mice were deeply anaesthetised with avertin and fixed on a cork plate. The mice 
were disinfected on the ventral side. Median thoracotomy was carried out to expose 
the heart. Intracardial perfusion was performed using 20 ml Ringer’s solution for each 
mouse. The perfusion was monitored by change in colour of the liver that turns yellow 
during perfusion. The head was cut at the atlantooccipital joint and the brain 
was removed carefully from the skull with the help of a hippocampus spoon 
and immediately frozen on dry ice. 
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3.2. METHODS FOR IFARCT MEASUREMET 
3.2.1. Histological slide 
 
The cryomicrotom was set to a temperature of -25 °C and frozen brains were placed 
in the microtom chamber to bring them to the same temperature before fixing. 
The brain was fixed with the help of tissue adhesive (tissue freezing medium Jung®). 
The coronal sections were cut with a thickness of 20 µm after each 400 µm, starting 
from rostral to caudal. The sections were placed on adhesion slides. 
 
3.2.2. Silver staining 
 
Silver impregnation solution was made by mixing 67.5 ml saturated 
(0.6 g in 50 ml H2O) lithium carbonate solution to 33.75 ml 10% silver nitrate solution. 
The precipitates formed from the solution were titrated by drop-wise adding 25% 
ammonia solution (approximately 3.6 ml). The addition of the ammonia solution is 
a critical step because the excesss of ammonia makes the staining faint but a little 
precipitate probably does not harm. Finally, 506.25 ml distilled water was added 
to the prepared solution. The solution was protected from the light. 
The developing solution was prepared by dissolving 6.6 g sodium citrate in 420 ml 
distilled water. Subsequently, a filtered solution of formaldehyde (120 ml 37%) was 
added and mixed well. Finally, 1.8 g hydroquinone and 90 ml acetone were added. 
The solution was mixed well at room temperature for around 30 to 60 minutes until 
the colour changed from yellow to orange. Both solutions were used only once for each 
30 slides and the staining was performed according to the following protocol (Vogel et 
al. 1999). 
• The sections were incubated 2 minutes in silver impregnation solution and shacked 
continuously. 
• After the incubation the slides were washed in distilled water 6 times for 1 minute 
each time. 
• Finally the slides were incubated for 3 minutes in developing solution followed 
by 3 washes in distilled water, each for one minute. 
The sections were air dried overnight. 
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3.2.3. Scanning and infarct measurement 
 
Stained sections were scanned at 300 dpi and the infarct area was measured using 
Image J software. The data were exported in Microsoft Excel. The silver staining 
represents not only the infarct area but also surrounding brain oedema as white area. 
Oedema was corrected as described (Swanson et al. 1990). Y=U-N+I. Where 
Y = Corrected infarct (mm3) 
U = Total area of non infarcted hemisphere (mm3) 
N = Total area of infarcted hemisphere (mm3) 
I = Direct measured infarct area (mm3). 
 
3.2.4. Statistical Analysis 
 
Data are illustrated as mean ± SEM. Statistical comparisons of three or more groups 
were made by analysis of variance (ANOVA) followed post test by Newman-Keuls 
Multiple Comparison Test. Two groups were compared by a two-tailed t-test 
with Bonferroni correction. Values are considered to be significant at p<0.05. 
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3.3. IMUOLOGICAL METHODS 
3.3.1. Microglial staining 
 
First, the phosphate buffered saline (PBS) 1x solution was prepared. It was mixed 8.0 g 
NaCl, 0.2 g KCl, 1.8 g Na2HPO4.2H2O and 0.24 g KH2PO4 and adjusted to pH 7.4 with 
HCl. Then distilled H2O was added up 1000 ml. 
 
Frozen sections were air dried for 5 minutes and then fixed with 4% PFA for 25 min 
at room temperature. The sections were rinsed three times with 1xPBS for 5 minutes 
each. Then the sections were permeabilized by incubating twice with 0.025% Triton 
X-100 in 1xPBS for 5 minutes each. Then the sections were blocked with 1% BSA 
in PBS for 90 minutes at 4°C. The sections were washed three times with PBS 
for 5 minutes each and were incubated over night at 4°C in a humid chamber 
with primary antibody (CD11b, Rat anti-mouse antibody, Serotec 
Cat. No. MCA711G). The primary antibody was diluted 1:100 in 5% BSA. On the next 
day, the sections were washed three times with PBS for 5 minutes each. The secondary 
antibody (Donkey anti rat alexa 488, Molecular Probes, Cat.No. 538955) was diluted 
1:200 in 5% BSA and added for 1 hour at room temperature. The sections were washed 
three times with PBS for 5 minutes each and then the sections were incubated with 
DAPI solution (1:5000 in water) for 10 minutes. The sections were washed three times 
with water for 2 minutes and then mounted with vector permanent mounting medium 
and dried for 1 hour. 
 
3.3.2. Fluorescence- activated cell sorting 
 
Fluorescence-activated cell sorting (FACS) is a specialized type of flow cytometry, 
which is a technique for counting and examining microscopic particles, such as cells 
and chromosomes. FACS is based upon the specific light scattering and fluorescent 
charateristics of each cell. All FACS in our experiment were provided 




4.1. Depletion of CD11b positive cells in CD11bDTR mice 
 
To investigate whether the effect of nicotinic acid is mediated by CD11b positive cells, 
the CD11bDTR transgenic mice were used in combination with diphtheria toxin (DT) 
treatment. 
This mouse strain expresses the human diphtheria toxin receptor (hDTR) 
from a monocyte/macrophage-specific CD11b promoter sequence so administration 
of DT selectively kills monocytes/macrophages (Duffield et al. 2005). 
In our case for selective depletion of CD11b positive cells, we injected diphtheria toxin 
(ip, 25 ng/g body weight) to both wild type and CD11bDTR mice for two consecutive 
days and then blood samples were taken for FACS analysis.. We found 92% reduction 
of CD11b positive cells in CD11bDTR mice when compared with the corresponding 
control mice. (Fig. 3)  
 
 
Fig. 3. Depletion of CD11b+ cells in CD11bDTR mice after DT treatment 
Diphtheria toxin (ip, 25 ng/g body weight) was injected to wt or CD11bDTR mice 
48 h and 24 h before analysis of blood cells. To count the cells, a FACS analysis was 
used and 92% of CD11b+ cells were reduced in CD11bDTR mice.  






























Fig. 4. Visualisation of Diphtheria toxin treatment and 	icotinic acid treatment 
Diphtheria toxin (IP, 25 ng/g body weight) was injected to WT or CD11bDTR mice 
48 h and 24 h before MCAO. Mice were treated with either vehicle (NaCl) or nicotinic 
acid (100 mg/kg, three times a day) for two days and than euthanized. 
Nicotinic acid (IP injection) 
 





Diphtheria toxin (IP injection) 
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4.2. CD11b depletion after DT treatment 
 
In order to analyze the impact of nicotinic acid on CD11b positive cells survival, we 
sought to quantify the amount of CD11b positive cells in predefined parts of brains 
of CD11bDTR and control mice after NA/vehicle treatment. As CD11b is a selective 
marker for monocyte macrophages and microglia, we used immunohistochemistry 
to label the cells.  
All mice were treated with DT and MCAO was performed. (Fig.4) 
For imaging fluorescent microscope (Leica DM4000B) was used. A reference sections 
from brain-atlas were taken and compared to cryosections of test mice. (Fig.5) Sections 
No. 25,27,29,31 referred to Paxinos Brain Atlas were used. 
For counting the CD11b+ cells 4 brains per group of mice and 4 sections from each 
brain were used. Quantification was performed in two predefined cortex parts 
of the ischemic hemisphere of each chosen brain section. (Fig. 5B) 
Mean of counted CD11b positive cells in a determined area among all four groups 
was compared. A significant difference in the number of CD11b positive cells was 
found in the WT control groups compared to others. No difference was observed 






    
Fig. 5: Example of brain sections for counting CD11b cells of the cortex 
(A) Section No. 29 reffered to Paxinos Brain Atlas (Bregma 0.26mm) 
(B) Section No. 31 reffered to Paxinos Brain Atlas (Bregma 0.02mm)  




A            B  
 
C            D 
Fig. 6: Illustration of brain pictures of CD11b+ cells in ischemic area. 
Magnifications 20X. Pictures are taken from fluorescent microscope from different 
mice groups after DT treatment and NA or vehicle treatment and CD11b 
immunostaining. CD11b+ cells presented as green signals were counted manually 
by Image J. 
(A) WT mice treated with vehicle (B) WT mice treated with NA  




















Fig. 7: CD11b depletion in the ischemic area of the brain after DT treatment 
Mean values of counted CD11b positive cells in predefined area in the ischemic area 
of the brain after immunohistochemistry with CD11b antigen.(1:100) First 
the fluorescent pictures were taken and cells were counted manually by using Image J. 
(n= 4 brains per group, 8 pictures per brain). CD11b+ cells are depleted after NA 
treatment in WT mice, in between CD11bDTR groups is no influence of NA treatment. 
Statistic was performed using ANOVA and Newman-Keuls Multiple Comparison Test. 




















































4.3. Depletion of blood derived CD11b+ cells leads to loss of protection 
by nicotinic acid   
 
In order to analyze the impact of NA on blood derived CD11b+ cells in cerebral 
ischemia, the infarct volume was measured. There was found significant difference 
in infarct volume in the NA treated control group but there was no significant 
difference in infarct volume in CD11bDTR mice group. To measure the infarct size 
silver staining was used, that visualizes the infarct area by darkening the surrounding 
tissue and lightening the infarct area (Fig.6) Around 8-10 brains per group was 
measured by using Image J program by using formula described in methods. 
After comparing the mean values of the infarct area in between the groups, the infarct 
area reduction after NA treatment was found only in WT mice. We found no significant 




    
 
Fig. 8: Samples of scanned brain sections with MCAO after silver staining. Lighter 


















































Fig. 9: Reduction of infarct area in ischemic brain after 	A treatment 
Results show significant reduction in the ischemic area only in WT mice treated 
with NA. It was found no difference between other groups. It demonstrates 
the protective effect of nicotinic acid only in WT mice. It shows no protective effect 






Stroke is one of the leading causes of death worldwide and its effective protective 
treatment is still missing. Nicotinic acid is widely used as a drug to influence the lipid 
spectrum and it is successfully used for prevention of cardiovascular diseases 
(Kamanna et al. 2008). Many studies have been done to determine its effect 
in atherosclerosis. Recently its receptor GPR109A was found and it mediates the effect 
of NA including its adverse effect- flushing. This receptor is located among other 
in adipose tissue and some immune cells including macrophages (Lorenzen et al. 2001). 
 
This study was designed to clarify the role of NA in the cerebral ischemia. 
To investigate whether macrophages are involved in its effect, we used WT 
and transgenic mice. Recently developed CD11bDTR mice have been succesfully used 
for specific depletion of CD11b+ cells (Duffield et al. 2005; Stoneman et al. 2007). 
Normally, the DTR receptor in mice bind DT poorly compared with the human 
and simian molecules (Saito et al. 2001), in CD11bDTR mice with transgenic 
expression of the human DT receptor (DTR) administration of DT selectively kills 
monocytes/macrophages in blood and some tissues (Stoneman et al. 2007). We treated 
these transgenic mice with DT and found 92% depletion of CD11b+ cells in their blood 
(Fig.3) which confirms previous findings. 
 
Macrophages and microglia play an important role in inflammatory phase of cerebral 
ischemia. In our work we sought to determine the impact of NA treatment 
on infiltration of macrophages after cerebral ischemia in normal WT mice and compare 
it with CD11b depleted mice (CD11bDTR). Since CD11b is a marker for macrophages 
and activated microglia (Rosen and Gordon 1990; Henkel et al. 2004), we stained brain 
sections with anti- CD11b antibody.  
There seems to be found that nicotinic acid treatment reduces the number 
of CD11b positive cells in the ischemic area of the brain of WT mice (Fig. 7) 
and in our experiment NA had no signifficant effect on the reduction of CD11b+ cells 
in CD11bDTR group when blood derived CD11b+ cells were already depleted. 
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It confirms previous finding that macrophages express GPR109A receptor which 
mediates the effect of NA (Lorenzen et al. 2002). 
However, in cerebral ischemia, brain macrophages consist partly of activated microglia 
and partly of immigrant macrophages. From our experiment it is not clear how many 
percent of CD11b+ cells depleted by NA treatment are microglia and how many 
percent are blood derived macrophages. According to CD11bDTR groups where 
we found no further reduction between treated and control group, it seems that NA has 
no effect on the number of microglia in our determined area of ischemic part 
of the brain. On the other hand, we don’t know have sufficient data for the impact 
of DT on the number of tissue microglia in the brain. 
To evaluate the impact of NA treatment on the number of activated microglia next 
experiments must be performed. It could be useful also to determine whereas 
NA treatment influences only activated microglia and if microglia in contralateral 
hemisphere are affected, too. Activation of microglia is a hallmark 
of neuroinflammation that worsens the damage in the post ischemic brain (Gehrmann et 
al. 1992). Anyway, the only definite way to distinguish between the two populations 
of macrophages and microglia is transplantation of labeled bone marrow. 
 
This study also provides knowledge about the role of the NA in the infarct area in post-
ischemic mice brain. In our experiment, NA reduced the infarct volume significantly 
in WT group. Surprisingly, the infarct area among other three groups (WT untreated 
and both CD11bDTR groups) was not significantly changed (Fig.9). It seems that 
depletion of blood derived CD11b + cells leads to loss of protection of NA treatment. 
 
The most recent finding, made by Lukasova et al., shows that NA has a potential 
to change the differentiation state of MF between M1 and M2. In their study concerning 
atherosclerosis they explored that NA induces reduced arginase-2, a marker 
for M1 macrophages (Lukasova et al.).  
In our lab we tried to perform immunohistochemistry with arginase-1 as a marker 
for M2 macrophages and iNOS as a marker for M1 (Hesse et al. 2001) but the exact 




In conclusion, from our experiments nicotinic acid seems to have a protective effect 
in ischemic brain which could be mediated by macrophages but to verify this effect 
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